Frontiers in Biology >

2016 , Vol. 11 >Issue 3: 256 - 259

DOI: https://doi.org/10.1007/s11515-016-1402-6

SHORT COMMUNICATION

A power analysis for future clinical trials on the potential adverse effects of SSRIs on amygdala reactivity

  • M. A. Bottelier 1,2 ,
  • A. Schrantee 2,3 ,
  • G. van Wingen 4 ,
  • H. G. Ruhé 4,5 ,
  • M. B. de Ruiter 2,3 ,
  • L. Reneman , 2,3
Expand
  • 1. Department of Child- and Adolescent Psychiatry, Triversum, Alkmaar, The Netherlands
  • 2. Brain Imaging Center, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
  • 3. Department of Radiology, Academic Medical Center, Amsterdam, The Netherlands
  • 4. Department of Psychiatry, Academic Medical Center, Amsterdam, The Netherlands
  • 5. Program for Mood and Anxiety Disorders, Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Received date: 31 Jan 2016

Accepted date: 25 Apr 2016

Published date: 05 Jul 2016

Copyright

2016 Higher Education Press and Springer-Verlag Berlin Heidelberg
Fold

Abstract

Treatment of adolescents with antidepressants may induce an increased risk for suicidality in this population. The activity of the amygdala during processing of emotional faces with functional Magnetic Resonance Imaging (fMRI) is a well-known measure of emotional dysregulation. Based upon data of our prematurely ended randomized clinical trial with fluoxetine (NTR3103) in anxious and or depressed girls (12–14 years of age) we calculated that with the found effect size of r = 0.66, compared to placebo, only 8 subjects are needed to demonstrate increased amygdala activity following 16 weeks of treatment with fluoxetine.

Key words： amygdala reactivity; SSRI; adverse effects; anxiety; depression

Cite this article

M. A. Bottelier , A. Schrantee , G. van Wingen , H. G. Ruhé , M. B. de Ruiter , L. Reneman . A power analysis for future clinical trials on the potential adverse effects of SSRIs on amygdala reactivity[J]. Frontiers in Biology, 2016 , 11(3) : 256 -259 . DOI: 10.1007/s11515-016-1402-6

Acknowledgments

We thank Dr. Anne Klomp for her work in setting up this RCT. This work was sponsored by personalized funding obtained by the Netherlands Organisation for Health Research and Development (Veni grant nr. 91686125 awarded to Liesbeth Reneman).

Compliance with ethics guidelines

Marco Bottelier declares that he received research funding from a private fund Suffugium. Anouk Schrantee, Guido van Wingen, Eric Ruhe, Michiel de Ruiter and Liesbeth Reneman declare that they have no conflict of interest.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study.

References

Publishing order | Descend order by publishing year | Descend order by cited within
1
Andersen S L, Navalta C P (2004). Altering the course of neurodevelopment: a framework for understanding the enduring effects of psychotropic drugs. Int J Dev Neurosci, 22(5-6): 423–440

DOI PMID

2
Ansorge M S, Zhou M, Lira A, Hen R, Gingrich J A (2004). Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science, 306(5697): 879–881

DOI PMID

3
Bottelier M A, Schouw M L J, Klomp A, Tamminga H G H, Schrantee A G M, Bouziane C, de Ruiter M B, Boer F, Ruhé H G, Denys D, Rijsman R, Lindauer R J L, Reitsma H B, Geurts H M, Reneman L (2014). The effects of psychotropic drugs on developing brain (ePOD) study: methods and design. BMC Psychiatry, <Date>Feb 19</Date>; 14(1): 48

DOI PMID

4
Bouet V, Klomp A, Freret T, Wylezinska-Arridge M, Lopez-Tremoleda J, Dauphin F, Boulouard M, Booij J, Gsell W, Reneman L (2012). Age-dependent effects of chronic fluoxetine treatment on the serotonergic system one week following treatment. Psychopharmacology, 221(2): 329–339

DOI PMID

5
Demenescu L R, Renken R, Kortekaas R, van Tol M J, Marsman J B, van Buchem M A, van der Wee N J, Veltman D J, den Boer J A, Aleman A (2011). Neural correlates of perception of emotional facial expressions in out-patients with mild-to-moderate depression and anxiety. A multicenter fMRI study. Psychol Med, 41(11): 2253–2264

DOI PMID

6
Hammad T (2004). Review and evaluation of clinical data: Relationship between psychotropic drugs and pediatric suicidality. Online document at: www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf

7
Klomp A, Tremoleda J L, Wylezinska M, Nederveen A J, Feenstra M, Gsell W, Reneman L (2012). Lasting effects of chronic fluoxetine treatment on the late developing rat brain: age-dependent changes in the serotonergic neurotransmitter system assessed by pharmacological MRI. Neuroimage, 59(1): 218–226

DOI PMID

8
Ma Y (2015). Neuropsychological mechanism underlying antidepressant effect: a systematic meta-analysis. Mol Psychiatry, 20(3): 311–319

DOI PMID

9
Ruhé H G, Koster M, Booij J, van Herk M, Veltman D J, Schene A H (2014). Occupancy of serotonin transporters in the amygdala by paroxetine in association with attenuation of left amygdala activation by negative faces in major depressive disorder. Psychiatry Res, 221(2): 155–161

DOI PMID

10
Shrestha S S, Nelson E E, Liow J S, Gladding R, Lyoo C H, Noble P L, Morse C, Henter I D, Kruger J, Zhang B, Suomi S J, Svenningsson P, Pike V W, Winslow J T, Leibenluft E, Pine D S, Innis R B (2014). Fluoxetine administered to juvenile monkeys: effects on the serotonin transporter and behavior. Am J Psychiatry, 171(3): 323–331

DOI PMID

11
Tao R, Calley C S, Hart J, Mayes T L, Nakonezny P A, Lu H, Kennard B D, Tamminga C A, Emslie G J (2012). Brain activity in adolescent major depressive disorder before and after fluoxetine treatment. Am J Psychiatry, 169(4): 381–388

DOI PMID

12
Wegerer V, Moll G H, Bagli M, Rothenberger A, Rüther E, Huether G (1999). Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life. J Child Adolesc Psychopharmacol, 9(1): 13–24, discussion 25–26

DOI PMID

Options
Outlines

/

〈 〉